EU/3/19/2246

Table of contents

About

On 9 January 2020, orphan designation EU/3/19/2246 was granted by the European Commission to Sanofi-Aventis Groupe, France, for romilkimab for the treatment of systemic sclerosis.

Key facts

Active substance
romilkimab
Disease / condition
Treatment of systemic sclerosis
Date of first decision
09/01/2020
Outcome
Positive
EU designation number
EU/3/19/2246

Sponsor's contact details

Sanofi-Aventis Groupe
54 Rue La Boetie
75008 Paris
France
Tel. +33 1697 45699
E-mail: question@sanofi.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating